Drug manufacturer Eli Lilly to leave Russia

According to Kommersant, the American drug manufacturer Eli Lilly has announced its intention to finally leave the Russian market. These data were confirmed by sources in the pharmaceutical market.

At the end of last month, preparations for the transfer of the business began, the top management in the representative office was replaced. According to an extract from the Unified State Register of Legal Entities, the CEO of Lilly Pharma LLC (the Russian structure of Eli Lilly) Irina Zaporozhets was replaced by Ekaterina Ibragimova. Some of the employees of Lilly Pharma, together with the top manager, will move to the structure that Swixx Biopharma will create for the distribution of Eli Lilly drugs in the Russian Federation.

The company announced the suspension of some of its medicines to Russia in March last year. Eli Lilly was going to transfer the proceeds from sales of its products in Russia to organizations providing humanitarian assistance to Ukraine. Like other pharmaceutical giants Bayer and Pfizer, the company also stopped all investments, advertising campaigns and new clinical trials in Russia. At the same time, such medicines as insulin "Humalog", antidiabetic "Trulicity", cancer drugs "Zenlistik", "Tsiramza", "Alimta" and "Gemzar", the manufacturer promised to continue to supply to the country.